Latest news
BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts - Fierce BiotechFierce Biotech · Fri, 07 Aug 2026 15:10:10 GMTLatigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s Journavx - Fierce BiotechFierce Biotech · Tue, 04 Aug 2026 11:55:09 GMTBlossomHill eyes $112M IPO harvest to fund Tagrisso challenger - Fierce BiotechFierce Biotech · Mon, 03 Aug 2026 13:18:47 GMT